Thesis Care, formerly known as Trovo Health, has successfully closed a $45 million Series A funding round, elevating its total capital raised to $60 million. The investment, led by Oak HC/FT, will fuel the company's mission to enhance clinical capacity through its innovative AI-powered care team platform. Thesis aims to help healthcare organizations scale their operations and deliver high-quality patient care more efficiently.
A Hybrid Approach to Care Delivery
Thesis Care introduces a novel model that combines advanced AI agents with the oversight of expert clinicians to manage complex healthcare tasks. This hybrid system is designed to handle high-impact clinical operations and care management, blending automated efficiency with indispensable human judgment. The platform effectively extends the capabilities of existing healthcare teams without replacing their core functions.
The company's technology is engineered to understand clinical context, enabling personalized patient engagement and the completion of critical workflow actions. A key feature is its ability to integrate seamlessly into existing systems, eliminating the need for staff to learn new tools. This ensures that providers can maintain their established processes while benefiting from reduced administrative workloads.
Fueling Expansion and Market Growth
According to CEO and co-founder Dr. Niren Gandra, the company reached a significant commercial turning point in the past year. This new infusion of capital is earmarked for accelerating commercial expansion and deepening the development of its unified technology platform. Thesis also intends to broaden its suite of specialized AI agents to cover more clinical areas.
The company has already established a strong foothold with numerous partners, including large provider organizations like US Heart & Vascular and Allied Digestive Health. Building on this success, Thesis Care is actively expanding its collaborations to include major health systems and health plan care teams. This strategic growth aims to bring its scalable solutions to a wider segment of the healthcare industry.
Validated by Partners and Performance
Healthcare partners have lauded the platform for its tangible impact on daily operations, noting that it takes significant work off staff plates. Clients report that patients arrive better prepared for appointments and that critical care gaps are more effectively closed. The unique combination of AI automation and a human care team is consistently cited as a key differentiator.
The platform's ability to deliver a clear return on investment is a major draw for healthcare organizations seeking to reduce administrative burdens. This value proposition has attracted strong investor confidence, with Andrew Adams of lead investor Oak HC/FT praising Thesis for its unique approach. The firm is recognized for building critical infrastructure for the future of scalable care delivery.
With its recent rebranding, substantial new funding, and a proven operational model, Thesis Care is well-equipped to address systemic challenges in healthcare. The company's focus on augmenting clinical teams with intelligent automation represents a significant advancement in the pursuit of efficiency. This strategic direction positions Thesis to play a pivotal role in shaping a more scalable future for patient care.